CytoDyn Inc (CYDY) Releases Quarterly Earnings Results, Misses Estimates By $0.03 EPS
CytoDyn Inc (NASDAQ:CYDY) released its quarterly earnings data on Tuesday. The biotechnology company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.03), Bloomberg Earnings reports.
Shares of CytoDyn (NASDAQ:CYDY) opened at 0.673 on Wednesday. The company’s 50 day moving average price is $0.65 and its 200 day moving average price is $0.65. CytoDyn has a one year low of $0.46 and a one year high of $0.84. The stock’s market capitalization is $102.81 million.
COPYRIGHT VIOLATION NOTICE: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright legislation. The legal version of this report can be read at https://www.thecerbatgem.com/2017/10/11/cytodyn-inc-cydy-releases-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.
Several research firms have recently weighed in on CYDY. Zacks Investment Research raised CytoDyn from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. ValuEngine raised CytoDyn from a “strong sell” rating to a “sell” rating in a research note on Thursday, September 7th. Finally, HC Wainwright set a $2.00 price objective on CytoDyn and gave the company a “buy” rating in a research note on Thursday, August 10th.
CytoDyn Company Profile
CytoDyn Inc is a clinical-stage biotechnology company. The Company is focused on the clinical development and commercialization of humanized monoclonal antibodies to treat Human Immunodeficiency Virus (HIV) infection. The Company’s lead product candidate, PRO 140, belongs to a class of HIV therapies known as entry inhibitors that block HIV from entering into and infecting certain cells.
Receive News & Stock Ratings for CytoDyn Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn Inc and related stocks with our FREE daily email newsletter.